You are viewing: Australia Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Australia Nuclear Medicine Market was valued at $134.9 Million in 2025 and projected to reach to $301.4 Million by 2030, representing a compound annual growth rate of 17.5%. Australia's nuclear medicine market is poised for substantial growth over the next five years, driven by technological advancements in imaging equipment and expanding clinical applications.

Australia Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Nuclear Medicine Market Trends and Insights

  • This represents a compound annual growth rate of 17.5%, significantly outpacing global trends.
  • Australia's healthcare infrastructure, coupled with increasing adoption of diagnostic imaging and therapeutic nuclear medicine procedures, is driving this accelerated growth trajectory across the forecast period. The Australian nuclear medicine sector is benefiting from rising prevalence of chronic diseases, aging demographics, and enhanced reimbursement frameworks that support nuclear imaging and therapy adoption.
  • Australia's investment in advanced healthcare technologies and skilled nuclear medicine professionals continues to strengthen market fundamentals.
  • Between 2025 and 2030, Australia is positioned as a key growth market within the Asia Pacific region, with expanding clinical applications in oncology, cardiology, and neurology driving demand for radiopharmaceuticals and imaging equipment. Australia's regulatory environment and healthcare spending patterns support sustained market expansion through 2030.
  • The country's emphasis on precision medicine and early disease detection aligns with nuclear medicine's clinical advantages, ensuring continued market momentum and investment in nuclear medicine infrastructure and capabilities..

Key Market Statistics

  • CAGR (2025-2030) 17.5% CAGR
  • Market Size, 2025 ~USD 134.9 Million
  • Forecast, 2030 ~USD 301.4 Million
  • Country Australia

Australia Nuclear Medicine Market Overview

Market Valuation Growth :

Australia's nuclear medicine market is valued at USD 134.9 million in 2025, with projections reaching USD 301.4 million by 2030, demonstrating exceptional market expansion potential.

Superior Growth Rate :

Australia's CAGR of 17.5% significantly outpaces the global nuclear medicine market growth rate of 15.1%, positioning the country as a high-growth market within the Asia-Pacific region.

Advanced Healthcare Infrastructure :

Australia's robust healthcare system and established diagnostic imaging capabilities provide a strong foundation for increased adoption of nuclear medicine procedures across major metropolitan and regional centers.

Rising Procedure Adoption :

Increasing demand for both diagnostic imaging and therapeutic nuclear medicine procedures is driving market expansion, supported by growing awareness among healthcare providers and patients.

Australia Nuclear Medicine Market Dynamics

  • The country's aging population and rising prevalence of chronic diseases such as cancer and cardiovascular conditions are creating sustained demand for nuclear medicine diagnostics and therapeutics.
  • Healthcare providers are increasingly investing in nuclear medicine infrastructure to meet patient needs and improve diagnostic accuracy. Government support for healthcare modernization and private sector investments in medical technology are expected to accelerate market expansion.
  • The integration of hybrid imaging technologies and personalized medicine approaches will further enhance market opportunities.
  • Australia's strong regulatory framework and emphasis on quality healthcare delivery position the market for continued double-digit growth through 2030..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Australia's nuclear medicine market is valued at USD 134.9 million in 2025, with projected growth to USD 301.4 million by 2030.
    • Australia demonstrates a 17.5% CAGR, substantially exceeding the global average of 15.1%, positioning it as a high-growth market.
    • Australia's aging population and rising chronic disease prevalence are primary drivers of nuclear medicine adoption and market expansion.
    • Australia's advanced healthcare infrastructure and supportive reimbursement policies create favorable conditions for sustained market growth through 2030.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    Australia Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    AUSTRALIA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES9.711.413.315.518.121.124.628.616.6
    DIAGNOSTIC & IMAGING CENTERS26.731.737.644.753.16374.788.418.6
    HOSPITALS58.368.380.193.9110128.9150.8176.317.1
    OTHER END USERS2.93.33.84.55.2678.116
    TOTAL97.7114.7134.9158.6186.4218.9257.1301.417.5

    Target Audience

    • Healthcare Providers & Hospital Networks : Hospital administrators and radiology departments need Australia-specific market data to justify investments in nuclear medicine equipment, staffing, and facility upgrades to meet growing demand.
    • Medical Device & Equipment Manufacturers : Equipment manufacturers require detailed Australia market insights to assess market size, growth potential, and competitive landscape for product launches and distribution strategies.
    • Investment & Private Equity Firms : Investors evaluating healthcare sector opportunities in Australia need validated market data and growth forecasts to assess ROI potential and identify acquisition or partnership targets.
    • Pharmaceutical & Diagnostic Companies : Pharmaceutical firms developing nuclear medicine therapeutics and diagnostic agents need Australia-specific market analysis to guide R&D investments and commercialization strategies.
    • Healthcare Consultants & Analysts : Consulting firms and market analysts require comprehensive Australia market data to support client advisory services, competitive benchmarking, and strategic planning initiatives.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for Australia's nuclear medicine market with verified CAGR of 17.5%, enabling accurate financial forecasting and investment decision-making for the 2025-2030 period.
    • Competitive Positioning Intelligence : Understand Australia's market performance relative to global trends (15.1% CAGR), identifying competitive advantages and market opportunities specific to the Australian healthcare landscape.
    • Strategic Market Entry Planning : Access detailed Australia-specific insights to develop targeted market entry strategies, including infrastructure assessment, regulatory considerations, and adoption patterns for nuclear medicine technologies.
    • Investment & Expansion Decisions : Leverage comprehensive Australia market data to justify capital investments, facility expansions, and resource allocation decisions within the high-growth nuclear medicine sector.
    • Stakeholder Communication : Present credible, market-validated data to investors, board members, and partners regarding Australia's nuclear medicine market potential and growth trajectory through 2030.

    Frequently asked questions

    What is the current size of Australia's nuclear medicine market?

    Australia's nuclear medicine market is valued at USD 134.9 million in 2025 and is projected to grow to USD 301.4 million by 2030.

    What is the growth rate of Australia's nuclear medicine market?

    Australia's nuclear medicine market is growing at a compound annual growth rate (CAGR) of 17.5% from 2025 to 2030.

    What factors are driving growth in Australia's nuclear medicine market?

    Key drivers include Australia's aging population, rising prevalence of chronic diseases, advanced healthcare infrastructure, supportive reimbursement policies, and expanding clinical applications in oncology, cardiology, and neurology.

    How does Australia's nuclear medicine market compare to global trends?

    Australia's 17.5% CAGR significantly exceeds the global average of 15.1%, making Australia one of the fastest-growing nuclear medicine markets in the Asia Pacific region.

    What clinical applications are expanding in Australia's nuclear medicine sector?

    Australia is experiencing increased adoption of nuclear medicine in oncology, cardiology, and neurology, driven by demand for diagnostic imaging and therapeutic procedures using radiopharmaceuticals.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status